AVROBIO Shares Jumps On Encouraging Data From Early-Stage Gene Therapy Study

  • AVROBIO Inc AVRO reported new interim data from the Phase 1/2 gene therapy trial of AVR-RD-04 for cystinosis.
  • Cystinosis is a condition characterized by the accumulation of the amino acid cystine (a building block of proteins) within cells. 
  • Excess cystine damages cells and often forms crystals that can build up and cause many organs and tissue problems.
  • AVR-RD-04 genetically modifies patients' hematopoietic stem cells (HSC) to express a functional version of cystinosin, the protein deficient in cystinosis patients. 
  • Related: After Fabry Trial Setback, Avrobio Hopes Rebound With Lysosomal Storage Disorder Data.
  • Preliminary data suggest that post gene therapy, functional cystinosin has been produced throughout the body, as evidenced by clinical measures in multiple tissues.
  • No adverse events related to the drug product have been reported.
  • Following discontinuation of cysteamine, average handgrip strength remained stable up to 27 months after dosing.
  • The first three patients observed a decline in cystine crystals in the skin and gastrointestinal mucosa biopsies.
  • Safety data from the five patients dosed indicate no AEs related to the drug product. All AEs were related to myeloablative conditioning, stem cell mobilization, underlying disease, or pre-existing conditions.
  • The company expects to initiate an AVROBIO-sponsored trial in 2023 in the U.S. 
  • AVROBIO's current plan involves a two-part strategy, beginning in a pre-renal transplant population followed by a post-renal transplant population.
  • Price Action: AVRO shares are up 3.26% at $0.81 during the market session on the last check Tuesday.

Posted In: Briefsgene therapyBiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.